The FDA's Medical Device Accelerator Is Growing Fast. Is Your Device Eligible Yet?

Aug 7
4 min read

Scientist in lab coat and blue gloves loads sample tubes into a lab machine, focused in a bright laboratory.

Getting an innovative medical device from concept to market has always involved a long stretch where developers are essentially guessing what the FDA wants to see, then finding out months later that they guessed wrong. The Total Product Life Cycle Advisory Program, known as TAP, was built specifically to close that gap. It's expanding faster than a lot of device developers seem to realize, and eligibility is changing often enough that assumptions from even a year ago may no longer hold.

Where the Program Stands Right Now

As of March 25, 2026, 115 devices are enrolled in the TAP Pilot. That's a meaningful jump for a voluntary program that only formally launched in October 2023 under the FDA's Center for Devices and Radiological Health, as one of the specific commitments agreed to between the FDA and industry as part of the Medical Device User Fee Amendments reauthorization, commonly known as MDUFA V.

The expansion isn't slowing down. On May 1, 2026, TAP opened up to two additional review divisions: the Division of Renal, Gastrointestinal, Obesity and Transplant Devices, and the Office of Surgical and Infection Control Devices. That's on top of the offices already participating, which include the Division of Ophthalmic Devices, the Office of Cardiovascular Devices, the Office of Neurological and Physical Medicine Devices, the Office of Orthopedic Devices, and the Office of Radiological Health. Each of those offices joined at a different point since the pilot's 2023 launch, and the pattern strongly suggests more offices will be added as the pilot continues.

What TAP Actually Gets You

TAP isn't simply a faster review queue in the traditional sense. It's something more structural: earlier and more frequent interactions with the FDA throughout the entire development process, proactive and strategic advice from a dedicated cadre of specifically trained CDRH advisors, and access to non-FDA stakeholders including clinicians, patient advocates, payers, and academic experts, brought into the conversation far earlier than they'd typically be involved under a traditional review pathway.

The stated long-term vision for TAP is to help spur more rapid development and more rapid, widespread patient access to safe, effective, high-quality medical devices of genuine public health importance. Critically, the goal isn't just faster regulatory clearance in isolation. It's aligning your regulatory strategy with reimbursement pathways and clinical adoption from the very start of development, instead of solving those problems separately and sequentially after authorization, which is where a lot of otherwise-cleared devices historically stall out commercially.

For developers, the practical effect is fewer expensive surprises late in the process. Issues that might otherwise delay authorization, whether related to evidence generation, submission quality, or FDA's expectations around a specific claim, get identified and addressed earlier, when they're still relatively cheap and fast to fix.

Who Actually Qualifies

TAP is currently limited to devices that already carry a Breakthrough Device designation or are part of the Safer Technologies Program, known as STeP, and only within the specific CDRH review offices currently participating in the pilot. That's an important and easy-to-miss detail: eligibility depends on two separate things at once, your device's designation status and which specific CDRH office reviews your particular device type.

That second factor is exactly why this is worth rechecking regularly rather than assuming last year's answer still holds. A device that wasn't eligible twelve months ago, simply because its review office hadn't joined the program yet, may be fully eligible now, given how quickly the participating office list has grown across 2025 and into 2026.

What to Do With This If You're Building a Device Right Now

Confirm your Breakthrough Device or STeP status directly. If you haven't pursued either designation and you're developing a genuinely innovative device, this is worth revisiting now, given how much TAP eligibility ultimately hinges on holding one of these two designations.
Check which CDRH office reviews your specific device type against the current, up-to-date list of participating offices. This list has changed multiple times over the past year alone, so don't rely on eligibility information that's more than a few months old.
If you're eligible now and weren't before, treat enrollment timing as a real strategic decision. Most of TAP's strategic value sits in getting into the program earlier in your development timeline, not after your submission package is already largely built and your key design decisions are locked in.
If you're not yet eligible, keep TAP on your active radar rather than writing it off. Given the pace of expansion across CDRH offices, your eligibility status could realistically change well before your device actually reaches submission stage.
Loop in your clinical and reimbursement teams early if you do enroll. TAP's structure is built specifically to bring those conversations forward, and getting the most value out of the program means actually using that earlier access rather than treating it as a bonus regulatory touchpoint.

The Bottom Line

The FDA rarely builds a voluntary program that gets bigger and more accessible over time by accident. TAP's steady expansion across review offices and enrolled devices is a real, concrete signal about where the agency wants to put its resources and attention for innovative medical devices. If your device could plausibly qualify, either now or in the near term, the earlier you're actually in the room, the more the program can genuinely do for you strategically, not just procedurally.

Figuring out whether your device and its current designation status line up with today's TAP eligibility criteria is a conversation worth having well before your development timeline forces decisions that are harder to unwind later.